Impact of Positive Resection Margins on Recurrence and Survival Following Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG PA-6 Randomized Controlled Trial.

Autor:	Lambert A; Department of Medical Oncology, Institut de Cancérologie de Lorraine and INSERM, UMR 1319 INSPIIRE, Université de Lorraine, Vandœuvre-lès-Nancy, France., Salleron J; Biostatistic Unit, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France., Harlé A; Service de Biologie Moléculaire des Tumeurs, Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN-Université de Lorraine, Vandœuvre-lès-Nancy, France., Biagi JJ; Department of Oncology, Queen's University, Canada., Leroux A; Department of Biopathology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France., Thomas J; Department of Biopathology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France., Monard L; R&D UNICANCER, Paris, France., Cros J; Department of Pathology, Hopital Beaujon - Université de Paris, INSERM U1149, Clichy, France., Marchal F; Departement of Surgical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France., Ayav A; Department of Hepatobiliary, Colorectal, and Digestive Surgery, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France., Conroy T; Department of Medical Oncology, Institut de Cancérologie de Lorraine and INSERM, UMR 1319 INSPIIRE, Université de Lorraine, Vandœuvre-lès-Nancy, France.
Jazyk:	angličtina
Zdroj:	Annals of surgery [Ann Surg] 2024 Jul 23. Date of Electronic Publication: 2024 Jul 23.
DOI:	10.1097/SLA.0000000000006449
Abstrakt:	Objective: This study investigated the correlation between positive resection margins and outcomes in patients with pancreatic ductal adenocarcinoma who underwent surgery and adjuvant chemotherapy according to the pivotal trial PRODIGE 24-CCTG PA-6. Background: The primary focus is on elucidating the prognostic significance of specific resection margins, including those associated with the superior-mesenteric vein (SMV), medial, and posterior pancreas. Methods: The analysis involved 400 patients across multiple centers in France and Canada. Surgical resection and subsequent adjuvant chemotherapy were core interventions. This study assessed the prognostic impact of resection margins, highlighting the significance of standardized pathology assessments. Additionally, the influence of chemotherapy regimen choice, comparing gemcitabine to mFOLFIRINOX, on the implications of positive resection margins was examined. Results: Only three margins, SMV (HR=1.48 95% CI [1.11;1.96], P<.001), medial (HR=1.92 95% CI [1.36;2.73], P<.001) and posterior (HR=1.65 95% CI [1.21;2.24], P=.002), had a significant prognostic impact on disease-free survival and were sufficient compared with the seven recommended margins (Kappa=0.90 95% CI [0.87; 0.94]). R1 status was significant independent prognostic factor for poorer survival in gemcitabine-treasted patients (HR=1.97 95% CI [1.23;3.16], P=.005) but lost its significance with mFOLFIRINOX (HR=1.46 95% CI [0.91;2.35], P=.114). Conclusions: All efforts should be made to evaluate the three margins of the highest prognostic value, with the others being secondary. A key finding of this study is the likely effect of mFOLFIRINOX on local invasion in operated patients, which seems to correct the impairment related to margin involvement, probably explaining the improvements in DFS and OS. Competing Interests: Conflict of interest: The authors declare they have no conflict of interest regarding the subject of this work. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu